prikaz prve stranice dokumenta Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
  Preuzmi
PDF 1.8 MB
Znanstveni rad - Izvorni znanstveni rad
Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
Bone Marrow Transplantation, 57 (2022), 5; 742-752. https://doi.org/10.1038/s41409-022-01604-x
(European Society for Blood and Marrow Transplantation (EBMT)) Passweg, Jakob R.; Baldomero, Helen; Chabannon, Christian; Corbacioglu, Selim; de la Cámara, Rafael; Dolstra, Harry; Glass, Bertram; Greco, Raffaella; Mohty, Mohamad; Neven, Bénédicte; Peffault de Latour, Régis; Perić, Zinaida; Snowden, John A.; Yakoub-Agha, Ibrahim; Sureda, Anna; Kröger, Nicolaus Više autora...

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Passweg, J. R., Baldomero, H., Chabannon, C., Corbacioglu, S., de la Cámara, R., Dolstra, H. ... Kröger, N. (2022). Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 57. (5), 742-752. doi: 10.1038/s41409-022-01604-x

Passweg, Jakob R., et al. "Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey." Bone Marrow Transplantation, vol. 57, br. 5, 2022, str. 742-752. https://doi.org/10.1038/s41409-022-01604-x

Passweg, Jakob R., Helen Baldomero, Christian Chabannon, Selim Corbacioglu, Rafael de la Cámara, Harry Dolstra, Bertram Glass, et al. "Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey." Bone Marrow Transplantation 57, br. 5 (2022): 742-752. https://doi.org/10.1038/s41409-022-01604-x

Passweg, J. R., et al. (2022) 'Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey', Bone Marrow Transplantation, 57(5), str. 742-752. doi: 10.1038/s41409-022-01604-x

Passweg JR, Baldomero H, Chabannon C, Corbacioglu S, de la Cámara R, Dolstra H, i sur.. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation [Internet]. 05.2022. [pristupljeno 03.12.2024.];57(5):742-752. doi: 10.1038/s41409-022-01604-x

J. R. Passweg, et al., "Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey", Bone Marrow Transplantation, vol. 57, br. 5, str. 742-752, Svibanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:376147. [Citirano: 03.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:376147
Podaci o radu
Naslov (engleski)Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
AutorJakob R. Passweg
AutorHelen Baldomero
AutorChristian Chabannon
AutorSelim Corbacioglu
AutorRafael de la Cámara
AutorHarry Dolstra
AutorBertram Glass
AutorRaffaella Greco
AutorMohamad Mohty
AutorBénédicte Neven
AutorRégis Peffault de Latour
AutorZinaida Perić
AutorJohn A. Snowden
AutorIbrahim Yakoub-Agha
AutorAnna Sureda
AutorNicolaus Kröger
KolaboracijaEuropean Society for Blood and Marrow Transplantation (EBMT)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Abstract In 2020, 45,364 HCT in 41,016 patients, 18,796 (41%) allogeneic and 26,568 (59%) autologous in 690 centers were reported. Changes observed were as follows: total number of HCT −6.5%, allogeneic HCT −5.1%, autologous HCT −7.5%, and were more pronounced in non-malignant disorders for allogeneic HCT and in autoimmune disease for autologous HCT. Main indications were myeloid malignancies 10,441 (25%), lymphoid malignancies 26,120 (64%) and non-malignant disorders 2532 (6%). A continued growth in CAR-T cellular therapies to 1874 (+65%) patients in 2020 was observed. In allogeneic HCT, the use of haploidentical donors increased while use of unrelated and sibling donors decreased. Cord blood HCT increased by 11.7% for the first time since 2012. There was a significant increase in the use of non-myeloablative but a drop in myeloablative conditioning and in use of marrow as stem cell source. We interpreted these changes as being due to the SARS-CoV-2 pandemic starting early in 2020 in Europe and provided additional data reflecting the varying impact of the pandemic across selected countries and larger cities. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual report of the EBMT reflects current activities useful for health care planning.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBone Marrow Transplantation
Brojčani podacivol. 57, br. 5, str. 742-752
p-ISSN0268-3369
e-ISSN1476-5365
DOIhttps://doi.org/10.1038/s41409-022-01604-x
URN:NBNurn:nbn:hr:105:376147
Datum objave publikacije2022-05
URL dokumentahttps://www.nature.com/articles/s41409-022-01604-x
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-07-19 09:46:06